Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Research dashboard

Search approved medicines for AI-predicted activity against four drug-resistant pathogens, and see what evidence is already documented for each one.

TryTuberculosisMRSAKlebsiella infectionE. coli infection

1,761

Approved medicines

Approved medicines matched to the FDA Orange Book, antimicrobials included

1,276

Medicines with ≥40% AI-predicted activity

Against at least one of the four supported pathogens; each medicine counted once

1,019

Repurposing candidates

Of those, the medicines that are not already antimicrobials

How the repurposing candidates are counted

  1. 1,761approved medicines

  2. 1,276with AI-predicted activity ≥40% against at least one pathogen

    − 485 below ≥40%, not counted

  3. 1,120not already antimicrobials

    − 156 already antimicrobials, set aside

  4. 1,019repurposing candidates

    − 101 needing review, kept in the library

Existing antimicrobials are identified from WHO ATC codes and FDA pharmacologic classes. Medicines needing review (neither source says whether they are antimicrobials) stay in the approved-medicine download, marked “unclassified”. They are not assumed to be non-antimicrobials, so they are not counted as candidates.

Downloads

Download approved medicines (CSV)1,761 rowsDownload repurposing candidates (CSV)1,019 rows

Pathogen coverage

A medicine can count under more than one

Registered studies

A registration describes a study; it does not establish a positive result.

Condition
When these studies started38,873 of 39,548 have a start date · most in 2021 (1,903)
193119812030

  • Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

    NCT07703436 · start 2027-03

    Registered record
    Registry ID
    NCT07703436
    Conditions
    Grade 2 IDH1-mutant Glioma; Grade 3 IDH1-mutant Glioma; Glioma; IDH1-mutant Glioma; Oligodendroglioma; Oligodendroglioma IDH-1 Mutant and 1/p19q-codeleted; Astrocytoma IDH Mutant Grade 3; Astrocytoma IDH Mutant Grade 2
    Interventions
    Safusidenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2027-03
    Completion
    2032-03
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGrade 2 IDH1-mutant Glioma; Grade 3 IDH1-mutant Glioma; Glioma; IDH1-mutant Glioma +4 more
    InterventionSafusidenib
    PhasePhase 2
    Registry statusNot yet recruiting

  • Penicillin to Prevent Early Rheumatic Heart Disease in School-Aged Children

    NCT07798232 · start 2027-02-01

    Registered record
    Registry ID
    NCT07798232
    Conditions
    Rheumatic Heart Disease in Children
    Interventions
    Oral Penicillin V
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2027-02-01
    Completion
    2032-03-01
    Enrolment
    9,622

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatic Heart Disease in Children
    InterventionOral Penicillin V
    PhasePhase 3
    Registry statusNot yet recruiting

  • Impact of the Antihistamine Desloratadine on the Quality of Life and Dysmenorrhea in Patients With Endometriosis

    NCT07821320 · start 2027-02

    Registered record
    Registry ID
    NCT07821320
    Conditions
    Endometriosis; Endometriosis (Diagnosis); Endometriosis and Dysmenorrhea; Endometriosis Associated Pelvic Pain
    Interventions
    Desloratadine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2027-02
    Completion
    2028-05
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis; Endometriosis (Diagnosis); Endometriosis and Dysmenorrhea; Endometriosis Associated Pelvic Pain
    InterventionDesloratadine; Placebo
    PhasePhase 2
    Registry statusNot yet recruiting

  • Pregnenolone to Target Concurrent PTSD and Stress Induced Alcohol Use in Veterans: A Dose Finding Study

    NCT06580444 · start 2027-01-15

    Registered record
    Registry ID
    NCT06580444
    Conditions
    Alcohol Use Disorder (AUD); Post Traumatic Stress Disorder (PTSD)
    Interventions
    Brexanolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2027-01-15
    Completion
    2027-12-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Use Disorder (AUD); Post Traumatic Stress Disorder (PTSD)
    InterventionBrexanolone
    PhasePhase 2
    Registry statusNot yet recruiting

  • Product Transference Study of Testagen™ TDS®-Testosterone

    NCT02733133 · start 2027-01-05

    Registered record
    Registry ID
    NCT02733133
    Conditions
    Hypogonadotropism
    Interventions
    Testagen® TDS Testosterone 5% HypoSpray®
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2027-01-05
    Completion
    2027-12
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypogonadotropism
    InterventionTestagen® TDS Testosterone 5% HypoSpray®
    PhasePhase 2
    Registry statusNot yet recruiting

  • Perioperative Nutrition Optimization for Reducing Complications After Surgical Fracture Fixation

    NCT07155447 · start 2027-01-04

    Registered record
    Registry ID
    NCT07155447
    Conditions
    Lower Extremity Fracture
    Interventions
    CEAA supplementation; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2027-01-04
    Completion
    2027-12-31
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLower Extremity Fracture
    InterventionCEAA supplementation; Placebo
    PhasePhase 3
    Registry statusNot yet recruiting

  • Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma

    NCT07691450 · start 2027-01-03

    Registered record
    Registry ID
    NCT07691450
    Conditions
    Recurrent Anaplastic Large Cell Lymphoma; Recurrent Enteropathy-Associated T-Cell Lymphoma; Recurrent Follicular Helper T-Cell Lymphoma; Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type; Recurrent Follicular Helper T-Cell Lymphoma, Follicular-Type; Recurrent Follicular Helper T-Cell Lymphoma, Not Otherwise Specified; Recurrent Hepatosplenic T-Cell Lymphoma; Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma; Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified; Recurrent Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma; Recurrent Primary Cutaneous Gamma-Delta T-Cell Lymphoma; Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma; Refractory Anaplastic Large Cell Lymphoma; Refractory Enteropathy-Associated T-Cell Lymphoma; Refractory Follicular Helper T-Cell Lymphoma; Refractory Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type; Refractory Fo
    Interventions
    Azacitidine; Belinostat; Biospecimen Collection; Computed Tomography; FDG-Positron Emission Tomography; Fludeoxyglucose F-18; Positron Emission Tomography; Pralatrexate; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2027-01-03
    Completion
    2029-11-24
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Anaplastic Large Cell Lymphoma; Recurrent Enteropathy-Associated T-Cell Lymphoma; Recurrent Follicular Helper T-Cell Lymphoma; Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type +14 more
    InterventionAzacitidine; Belinostat; Biospecimen Collection; Computed Tomography +5 more
    PhasePhase 1
    Registry statusNot yet recruiting

  • Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer

    NCT07745296 · start 2027-01-02

    Registered record
    Registry ID
    NCT07745296
    Conditions
    Biliary Tract Cancer (BTC)
    Interventions
    Futibatinib; Ivosidenib + Capecitabine; Zanidatamab + Capecitabine; Capecitabine (Xeloda)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2027-01-02
    Completion
    2033-07-02
    Enrolment
    990

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBiliary Tract Cancer (BTC)
    InterventionFutibatinib; Ivosidenib + Capecitabine; Zanidatamab + Capecitabine; Capecitabine (Xeloda)
    PhasePhase 3
    Registry statusNot yet recruiting

  • A Randomized Clinical Trial of Ex Vivo Corneal Cross-Linking of Donor Keratoplasty Tissue for Keratoconus Used for Keratoplasty in Keratoconus Patients

    NCT04584125 · start 2027-01-01

    Registered record
    Registry ID
    NCT04584125
    Conditions
    Keratoconus
    Interventions
    Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% with UV light; Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% without UV light
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2027-01-01
    Completion
    2028-11-30
    Enrolment
    216

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKeratoconus
    InterventionRiboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% with UV light; Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% without UV light
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Nebulised Colistimethate Sodium to Prevent Pediatric Ventilator-associated Pneumonia

    NCT06488794 · start 2027-01-01

    Registered record
    Registry ID
    NCT06488794
    Conditions
    Ventilator Associated Pneumonia
    Interventions
    colistimethate sodium; 0.9% Saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Not yet recruiting
    Start
    2027-01-01
    Completion
    2028-12-31
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator Associated Pneumonia
    Interventioncolistimethate sodium; 0.9% Saline
    PhasePhase 2 / Phase 3
    Registry statusNot yet recruiting

  • RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients

    NCT07056478 · start 2027-01-01

    Registered record
    Registry ID
    NCT07056478
    Conditions
    Sarcopenia in Elderly
    Interventions
    Denosumab (Prolia); Zoledronic acide (Aclasta)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2027-01-01
    Completion
    2030-01-01
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcopenia in Elderly
    InterventionDenosumab (Prolia); Zoledronic acide (Aclasta)
    PhasePhase 3
    Registry statusNot yet recruiting

  • A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia

    NCT07084831 · start 2027-01-01

    Registered record
    Registry ID
    NCT07084831
    Conditions
    Schizophrenia; Psychosis; Cognitive Impairment
    Interventions
    Xanomeline/trospium
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2027-01-01
    Completion
    2029-07-01
    Enrolment
    171

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Psychosis; Cognitive Impairment
    InterventionXanomeline/trospium
    PhasePhase 3
    Registry statusNot yet recruiting

  • Relaxin Therapy for Atrial Fibrillation

    NCT07359872 · start 2027-01-01

    Registered record
    Registry ID
    NCT07359872
    Conditions
    Atrial Fibrillation (AF); Arrhythmia; Oxidative Stress; Stroke; Major Cardiovascular Event; Heart Failure; Catheter Ablation; Ablation of Atrial Fibrillation
    Interventions
    Relaxin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2027-01-01
    Completion
    2030-12-31
    Enrolment
    208

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation (AF); Arrhythmia; Oxidative Stress; Stroke +4 more
    InterventionRelaxin; Placebo
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • Prediction and Prevention of Bloodstream Infections After Kidney Transplantation

    NCT07407673 · start 2027-01-01

    Registered record
    Registry ID
    NCT07407673
    Conditions
    Kidney Transplant Infection; Bloodstream Infection; Kidney Transplant; Kidney Transplant Recipients; Infection; Urinary Tract Infection(UTI); Urinary Tract Infection Bacterial; Antibiotic Prophylaxis; Bacteriuria
    Interventions
    Pivmecillinam; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2027-01-01
    Completion
    2041-07
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Transplant Infection; Bloodstream Infection; Kidney Transplant; Kidney Transplant Recipients +5 more
    InterventionPivmecillinam; Placebo
    PhasePhase 3
    Registry statusNot yet recruiting

  • Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer

    NCT07419880 · start 2027-01-01

    Registered record
    Registry ID
    NCT07419880
    Conditions
    Triple -Negative Breast Cancer
    Interventions
    Cromolyn, TQB2102, and Panpulimab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2027-01-01
    Completion
    2028-06-30
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTriple -Negative Breast Cancer
    InterventionCromolyn, TQB2102, and Panpulimab
    PhasePhase 2
    Registry statusNot yet recruiting

AI-predicted activity is a model’s estimate that a molecule is active against a pathogen in the laboratory. It is not clinical effectiveness. The models describe each pathogen species; the data behind them rarely records resistant strains.